ABSTRACT Five bis-arylimidamides were assayed as anti-Trypanosoma cruzi agents by in vitro, in silico, and in vivo approaches. None were considered to be pan-assay interference compounds. They had a favorable pharmacokinetic landscape and were active against trypomastigotes and intracellular forms, and in combination with benznidazole, they gave no interaction. The most selective agent (28SMB032) tested in vivo led to a 40% reduction in parasitemia (0.1 mg/kg of body weight/5 days intraperitoneally) but without mortality protection. In silico target fishing suggested DNA as the main target, but ultrastructural data did not match.
A
ccording to the World Health Organization (1), more than 6 million people worldwide are infected with Trypanosoma cruzi, the etiological agent of Chagas disease (CD), and less than 1% are treated with the current available drugs, nifurtimox and benznidazole (Bz), which exhibit several limitations, including low efficacy at the later disease stage and toxic events (2, 3) . There is an urgent need to develop alternatives for the treatment of this silent and progressive neglected agent of disease. Aromatic diamidines have antitumor and broad-spectrum antimicrobial activities, and some of their analogues, such as arylimidamides (AIAs), have greater potency and selectivity against intracellular parasites (4) . Thus, our aim was to evaluate the biological effects of five novel bis-AIAs (Table 1) against T. cruzi by integrating in vitro, in silico, and in vivo tools. 2EVK008, 36DAP015, 27SMB078, 28SMB032, and 31DAP069 were synthesized (see Fig. S1 in the supplemental material) as reported previously (5) (6) (7) (8) , and experimental details are provided in the supplemental material.
The first evaluation of bloodstream trypomastigotes (BTs) from the Y strain (discrete typing unit II [DTU II]) showed that 4 out of 5 compounds are more active than Bz after 24 h of incubation. 2EVK008, 31DAP069, and 36DAP015 also are "fast killers" (with a 50% effective concentration [EC 50 ] of Ͻ10 M after 2 h of incubation), displaying high potency ( Table 1) . The activity against intracellular forms (e.g., the Tulahuen strain [DTU VI], which expresses the Escherichia coli ␤-galactosidase [␤-Gal] gene) demonstrated that 2EVK008, 28SMB032, 36DAP015, and 31DAP069 have EC 50 s lower than that of Bz (Table 1) . 31DAP069 and 36DAP015 exhibit considerable mammalian host cell toxicity (with a 50% lethal concentration [LC 50 ] ranging between 9 and 12 M against mouse L929 fibroblasts), while 28SMB032 is less toxic according to alamarBlue assays (9) and exhibits high selectivity indexes (SIs) of Ͼ54 and 285 for BT and intracellular forms, respectively. The trypanocidal effect of 28SMB032 was confirmed toward different (10, 11) . The AIA combination with Bz assessed using a fixed-ratio method (12) gave a mean sum of fractional inhibitory concentration indexes (x⌺FICI) of 0.95, conferring a status of no interaction (Table S1) .
In silico adsorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis and analysis with pan-assay interference compounds (PAINS) were done under different Web services: those of admetSAR (http://lmmd.ecust.edu.cn:8000), ACD/I-Lab, Pred-hERG (http://labmol.com.br/predherg/), PROTOX (http://tox.charite.de/tox/), and False Positive Remover (13) (14) (15) (16) (17) (18) (19) (20) (21) . All compounds were predicted to be noncarcinogenic, nongenotoxic, non-human-ERG (hERG) blockers, and noninhibitors of most cytochrome P450 isoforms, besides having acceptable rodent toxicity by the oral route, moderate human intestinal absorption, and a favorable volume of distribution (Table  S2) . None contain PAINS substructures, and consequently, there is little probability that their biological activities are artifacts; they thus have a low probability of binding/ inhibiting nonspecific targets (22) .
For in silico prediction, a pool of potential targets in T. cruzi was generated. First, all three-dimensional (3D) structures available in the Protein Data Bank (PDB; http://www .rcsb.org/pdb/) with cocrystallized ligands were selected. Then, a bibliographic search with similar bioisosteric characteristics of the studied amidines was performed. Based on the concept that similar ligands bind to similar targets, three targets involved in the metabolism of putrescine or spermidine (23) and four known targets of pentamidine and analogues were identified. Homology models were built for trypanothione synthetase, POT1.1, POT1.2, and aquaporin ( Fig. S2 ; Table S3 ). They were validated statistically using PROCHECK analysis (Fig. S3) (24) . The overall stereochemical properties of the generated models are highly reliable and useful for a prospective target-fishing study. The final target pool is summarized in Table S4 and consisted of 30 potential targets, including enzymes and regulatory proteins. Molecular docking studies (Table 2) showed by the GlideScore energies the AIAs' high affinity to DNA, with energies ranging between Ϫ12.08 and Ϫ9.62 kcal/mol, which is next to that of pentamidine (Ϫ11.17 kcal/mol), a well-known DNA binder. Following in sequence of binding energy values were farnesyltransferase (PFT), spermidine synthase (SdpS), sterol 14-alpha demethylase (CYP51), and UDP-galactopyranose mutase (UGM). To explore earlier cellular insults induced by the AIAs, ultrastructural analysis was done on BT forms exposed for 2 h (using the EC 50 from 24 h) with the best fast killers, 31DAP069 and 36DAP015, besides the most selective agent, 28SMB032. Scanning electron microscopy showed that 31DAP069 and 36DAP015 did not induce morphological modifications ( Fig. 2B and C) . Although most BTs exposed to 28SMB032 exhibited a profile similar to that of untreated ones ( Fig. 2A1 and A2 ), some morphological alterations included shortening ( Fig. 2D1 and D4 ) and twisting ( Fig. 2D2 and D3 ) of the parasite bodies. Transmission electron microscopy (TEM) revealed that untreated parasites presented characteristic morphology (Fig. 3A1 and A2 ). BTs exposed to amidines exhibited similar cellular alterations regardless of the in vitro potency (EC 50 s), including distension of the flagellar pocket, plasmatic and nuclear membrane dilation, distortions of the Golgi apparatus, the presence of concentric membranes and myelin figures, a large number of intracellular vesicles, and an altered profile of the endoplasmic reticulum surrounding cytoplasmic components (Fig. 3B1 to D8) , suggestive of an autophagy phenotype that deserves further analysis.
Literature data demonstrate that classical amidines, such as pentamidine (25) and some analogues (26) , strongly interact with DNA in a binding mode very similar to those of hydrophobic methylene groups and with rings tightly bound to the minor groove. Additionally, findings revealed that although some of the most active AIAs were not good DNA binders, some AIAs strongly altered DNA topology, impairing functionality (27) . Even the fast and potent AIAs did not induce ultrastructural alterations of the DNA, and it may be possible that TEM is not sensitive enough for detecting minor topology alterations detected in silico and/or that there is a lack of translation among in silico and whole-cell-based assays. In order to deeply explore the binding mode and effect, thermodynamic studies are needed. Plus, the observed in vitro activity can involve other predicted targets, such as UGM, CYP51, PFT, and SdpS, related to T. cruzi fitness and pathogenesis; some of their inhibitors, such as the CYP51 inhibitors , and D6), concentric membranar structures and myelin figures in the cytosol (black arrows in panels B2, B3, C3, and D4), disruption of the Golgi apparatus (asterisk in panels C1 and D7), an endoplasmic reticulum surrounding cytosolic structures (arrowheads in panels C2 and D3), and detachment of the nuclear (short arrow in panel D8) and plasma (short arrow in panel D6) membranes. No alterations were detected in subpellicular microtubules (thin arrows in panel D5) and on the parasite kinetoplast DNA (kDNA) (double arrows in panels D1 and D2). G, Golgi cisternae; M, mitochondria; N, nuclei; F, flagellum. Bars ϭ 500 nm. .) showed a toxic profile, leading to Ͼ83% of the animals dying less than 24 h after drug administration. Gross pathology showed a large amount of yellow deposits of the AIA at the peritoneum as well as gastrointestinal bleeding and signs of acute renal failure with kidney atrophy (data not shown). However, this AIA, given as monotherapy at 0.1 mg/kg (i.p., with DMSO as the vehicle), led to a 40% reduction of the parasite load at the peak (8 days p.i.). Although in vitro outcomes did not fully translate in the experimental animal models, the molecule optimization may reduce the toxicity issues of this class of compounds and contribute to alternative treatments for CD.
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